Brokerages Set Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Price Target at $5.00

Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) have earned an average recommendation of “Hold” from the four research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $5.00.

Several equities research analysts recently issued reports on the company. Zacks Research raised Citius Pharmaceuticals to a “hold” rating in a research report on Tuesday, May 19th. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Citius Pharmaceuticals in a research report on Monday, May 18th. D. Boral Capital reissued a “buy” rating and set a $6.00 price target on shares of Citius Pharmaceuticals in a research report on Wednesday, March 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Friday, March 27th.

Citius Pharmaceuticals Stock Performance

Citius Pharmaceuticals stock opened at $0.70 on Monday. The stock has a market cap of $19.25 million, a P/E ratio of -0.33 and a beta of 1.05. The stock has a 50 day moving average of $0.76 and a 200-day moving average of $0.88. Citius Pharmaceuticals has a 52 week low of $0.48 and a 52 week high of $2.48.

Citius Pharmaceuticals (NASDAQ:CTXR) last released its earnings results on Friday, May 15th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.67). The firm had revenue of $1.67 million during the quarter, compared to the consensus estimate of $10.23 million. As a group, equities analysts predict that Citius Pharmaceuticals will post -1.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Citius Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in CTXR. XTX Topco Ltd acquired a new stake in shares of Citius Pharmaceuticals during the 2nd quarter valued at approximately $32,000. NewEdge Advisors LLC acquired a new stake in shares of Citius Pharmaceuticals during the 2nd quarter valued at approximately $40,000. Asset Advisory Group Inc. acquired a new stake in shares of Citius Pharmaceuticals during the 4th quarter valued at approximately $46,000. Finally, Heights Capital Management Inc. acquired a new stake in shares of Citius Pharmaceuticals during the 4th quarter valued at approximately $622,000. 16.88% of the stock is owned by institutional investors and hedge funds.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.